Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-dose Ad26.ZEBOV and MVA-BN Filo vaccination regimen in infants
PACTR201905827924069Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 2
01
Overview
Phase 2 trial of zabdeno and Mvabea in Ebola virus disease (EVD) (2 arms), sponsored by Janssen Pharmaceutical. Started Jul 2019; status: completed.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR201905827924069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201905827924069.